Posted on 16/06/2009 in Pharmaceutical Company Product News Boehringer Ingelheim will use its expertise along with that of Vitae Pharmaceuticals to strengthen its neuroscience portfolio, it has stated.
In order to research and develop beta-secretase (BACE) inhibitors for the treatment of Alzheimer?s disease, the two companies have entered a worldwide collaboration.
Under the terms of the agreement, Boehringer Ingelheim will give Vitae $42 million (25.57 million pounds) in upfront and near-term payments. The latter will also be able to receive a further $200 million at various clinical and regulatory milestones.
After the firms have worked together on the product, Boehringer Ingelheim will look after the commercialisation of it. The company asserted it would be able to capitalise on its marketing and sales ability.
Dr Manfred Haehl, corporate senior vice-president of Boehringer Ingelheim's research & development and medicine divisions, claimed the aim was to create new treatments for sufferers of the debilitating illness.
"It is part of our core development strategy to establish long-term alliances with innovative companies that broaden the scope of our own exciting pipeline successes," he said.
Meanwhile, the company has recently discussed data showing an investigational combination of telmisartan and amlodipine can lower blood pressure for 24 hours and is well tolerated by patients.Other news stories from 16/06/2009
Read more in the Zenopa News Archive
How this news is generated
|
